A phase II trial of dose-reduced nab -paclitaxel for patients with previously treated, advanced or recurrent gastric cancer (OGSG 1302)

ConclusionTri-weeklynab-PTX with a reduced dose (220  mg/m2) is not recommended for AGC in a second-line or later setting, despite demonstrating less toxicity than at 260  mg/m2.Clinical trial registrationThe OGSG1302 trial was registered with UMIN-CTR as UMIN000000714.
Source: International Journal of Clinical Oncology - Category: Cancer & Oncology Source Type: research